Vizient has ranked Rush University Medical Center #1 for quality among the nation’s most prestigious academic medical centers. Learn more.
How you can devise a cancer prevention action plan.
How to love yourself — and your selfies — without filters or fillers.
Aneurysmal Subarachnoid Hemorrhage Treatment Study
Clinical Trial Title:
ASTROH
Clinical Trial Protocol ID:
16031106
Clinical Trial Investigator Name:
George A. Lopez, MD
Clinical Trial Protocol Description:
The purpose of this study is to investigate the safety and clinical effect of a continuous low-dose intravenous heparin treatment in patients who have an aneurysmal subarachnoid hemorrhage. Nationwide, 88 patients will be recruited for this study. At Rush University, we expect to recruit 8 patients. Treatment will be assigned randomly between low-dose intravenous heparin and prophylactic subcutaneous heparin (standard of care).
Clinical Trial Eligibility Criteria:
In order to participate you must meet the following criteria:
- Are between the ages of 18 and 70 years old.
- Have a ruptured saccular aneurysm confirmed by angiography and repaired by coiling.
- Have GCS 13-15 without focal deficit after repair.
- Have odified Fisher 3 only (minimal IVH allowed).
You will be excluded from the study if any of the following criteria apply to you:
- Have clipping or intracranial stent placement.
- Have anti-platelet or oral anticoagulation prior or during coil (single dose 325mg ASA is OK).
- Have a body weight < 50 or > 150kg.
- Have historical mRS ≥ 2.
This is a partial list of inclusion and exclusion criteria.
Clinical Trial Area:
Stroke and Cerebrovascular Disease
Contact Phone:
(312) 942-6731
Contact Name:
Rebecca Holtz (Study Coordinator)